Overview

Location [1]
4p16.3
Pathways
Receptor tyrosine kinase/growth factor signaling, Kinase fusions
Protein [2]
Fibroblast growth factor receptor 3
Synonyms [1]
CD333, HSFGFR3EX, ACH, CEK2, JTK4

The fibroblast growth factor receptor 3 (FGFR3) gene encodes one member of the FGF receptor tyrosine kinase family, which includes four kinases: FGFR1, FGFR2, FGFR3, and FGFR4. FGFRs are involved in downstream signaling via the MAP kinase, JAK/STAT, and PI3K/AKT pathways. FGFR3 gene aberrations have been reported in urothelial, breast, head and neck, lung, brain, gastric, pancreatic, colorectal, kidney, endometrial, ovarian, and cervical cancers and are known to be highly prevalent in bladder cancers.

FGFR3 is altered in 2.53% of all cancers with bladder carcinoma, colorectal adenocarcinoma, non-small cell lung carcinoma, breast carcinoma, and melanoma having the greatest prevalence of alterations [3].

FGFR3 GENIE Cases - Top Diseases

The most common alterations in FGFR3 are FGFR3 Mutation (2.67%), FGFR3 S249C (0.54%), FGFR3 Amplification (0.31%), FGFR3 R248C (0.14%), and FGFR3 Loss (0.13%) [3].

FGFR3 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of FGFR3 in Diseases

Urothelial Carcinoma +

Bladder Carcinoma +

Multiple Myeloma +

Malignant Solid Tumor +

Plasma Cell Leukemia +

Cancer +

Non-Small Cell Lung Carcinoma +

Lymphoma +

Breast Carcinoma +

Smoldering Plasma Cell Myeloma +

Squamous Cell Lung Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Acute Myeloid Leukemia +

Chronic Lymphocytic Leukemia +

Glioma +

Myelodysplastic Syndromes +

Acute Lymphoblastic Leukemia +

Non-Hodgkin Lymphoma +

Transitional Cell Carcinoma +

Urethral Urothelial Carcinoma +

Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +

Bladder Urothelial Carcinoma +

Endometrial Carcinoma +

Anaplastic Astrocytoma +

Chronic Myeloid Leukemia +

Myeloproliferative Neoplasm +

Anaplastic Oligodendroglioma +

Gastric Carcinoma +

Glioblastoma +

Extrahepatic Cholangiocarcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Intrahepatic Cholangiocarcinoma +

Cholangiocarcinoma +

Small Cell Lung Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Diffuse Intrinsic Pontine Glioma +

Myelofibrosis +

Myeloma +

Plasmacytoma +

Prolymphocytic Leukemia +

Renal Pelvis Urothelial Carcinoma +

Small Lymphocytic Lymphoma +

T-Cell Prolymphocytic Leukemia +

Ureter Urothelial Carcinoma +

Waldenstrom Macroglobulinemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.